Albumin-based drug delivery: harnessing nature to cure disease

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • Maja Thim Larsen
  • ,
  • Matthias Kuhlmann
  • ,
  • Michael Lykke Hvam
  • ,
  • Ken Howard

The effectiveness of a drug is dependent on accumulation at the site of action at therapeutic levels, however, challenges such as rapid renal clearance, degradation or non-specific accumulation requires drug delivery enabling technologies. Albumin is a natural transport protein with multiple ligand binding sites, cellular receptor engagement, and a long circulatory half-life due to interaction with the recycling neonatal Fc receptor. Exploitation of these properties promotes albumin as an attractive candidate for half-life extension and targeted intracellular delivery of drugs attached by covalent conjugation, genetic fusions, association or ligand-mediated association. This review will give an overview of albumin-based products with focus on the natural biological properties and molecular interactions that can be harnessed for the design of a next-generation drug delivery platform.

Original languageEnglish
JournalMolecular and Cellular Therapies
Volume4
Issue3
Pages (from-to)3
ISSN2052-8426
DOIs
Publication statusPublished - 27 Feb 2016

See relations at Aarhus University Citationformats

ID: 98225110